Document is current

Article History

Received: 26 November 2024

Accepted: 3 May 2025

First Online: 20 May 2025

Declarations

:

: Y.Y. has received honoraria from Ono Pharmaceutical, Takeda Pharmaceutical. E.I. has received honoraria from Chugai Pharmaceutical and AstraZeneca. K.T. has received honoraria from Chugai Pharmaceutical, AstraZeneca, Ono Pharmaceutical, Bristol-Myers Squibb, Eli Lilly, Takeda Pharmaceutical, Daiichi-Sankyo, and MSD. I.O. has received honoraria and research funding from Chugai Pharmaceutical, AstraZeneca, Ono Pharmaceutical, Taiho Pharmaceutical, MSD, Eli Lilly, Boehringer Ingelheim, and Bristol-Myers Squibb as well as honoraria from Pfizer and research funding from Astellas, Novartis, Takeda Pharmaceutical, Daiichi Sankyo, Haihe Biopharma, and AbbVie. The remaining authors declare no financial or non-financial competing interests.

: Animal studies: Animal experiments were approved by the Kyushu University Animal Experiment Committee (approval number: A23-422–4) and were performed in accordance with Kyushu University Animal Experiment Regulations, related laws and regulations, and ARRIVE (Animal Research: Reporting of In Vivo Experiments) guidelines. Approval of the research protocol by an institutional review board: The study was approved by the Ethics Committee of Kyushu University and Kyushu University Hospital (ethics approval ID: 2021–289, 22,343–00).

: Informed consent was obtained from all healthy donors.